title: Longer survival in patients with breast cancer with cyclin d1 over-expression after tumor recurrence: longer, but occupied with disease.
abstract: OBJECTIVE
  The effect of cyclin D1 overexpression on breast cancer outcomes and prognosis is controversial, even though amplification of the cyclin D1 gene, CCND1, has been shown to be associated with early relapse and poor prognosis. In this study, we examined the relationship between cyclin D1 overexpression and disease-specific survival (DSS). We also analyzed survival in patients who experienced recurrence.
  
  
  METHODS
  We retrospectively analyzed data from patients diagnosed with ductal carcinoma between April 2005 and December 2010. We examined clinicopathologic factors associated with cyclin D1 overexpression and analyzed the influence of cyclin D1 on recurrence-free survival and DSS.
  
  
  RESULTS
  We identified 236 patients diagnosed with primary breast cancer who completed all phases of their primary treatment. Cyclin D1 overexpression was significantly associated with longer DSS (5-year DSS, 89.9% in patients without cyclin D1 overexpression vs. 98.9% in patients with cyclin D1 overexpression; p=0.008). Multivariate analysis also found that patients with cyclin D1 overexpressing tumors had significantly longer disease-specific survival than patients whose tumors did not overexpress cyclin D1, with a hazard ratio for disease-specific mortality of 7.97 (1.17-54.22, p=0.034). However, in the group of patients who experienced recurrence, cyclin D1 overexpression was not significantly associated with recurrence-free survival. Cyclin D1 overexpression was significantly associated with increased survival after disease recurrence, indicating that cyclin D1 overexpression might be indicative of more indolent disease progression after metastasis.
  
  
  CONCLUSIONS
  Cyclin D1 overexpression is associated with longer DSS, but not recurrence-free survival, in patients with breast cancer. Longer postrecurrence survival could explain the apparent inconsistency between DSS and recurrence-free survival. Patients with cyclin D1-overexpressing tumors survive longer, but with metastatic disease after recurrence. This information should spark the urgent development of tailored therapies to cure these patients.
authors.affiliation: Department of Surgery, Yonsei University Wonju College of Medicine, Wonju, Korea.
authors.forename: Jaesik
authors.initials: J
authors.lastname: Chung
authors.affiliation: Department of Surgery, Yonsei University Wonju College of Medicine, Wonju, Korea.
authors.forename: Hany
authors.initials: H
authors.lastname: Noh
authors.affiliation: Department of Pathology, Yonsei University Wonju College of Medicine, Wonju, Korea.
authors.forename: Kwang Hwa
authors.initials: KH
authors.lastname: Park
authors.affiliation: Institute of Lifestyle Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
authors.forename: Eunhee
authors.initials: E
authors.lastname: Choi
authors.affiliation: Department of Surgery, Yonsei University Wonju College of Medicine, Wonju, Korea.
authors.forename: Airi
authors.initials: A
authors.lastname: Han
keywords: Breast neoplasms; Cyclin D1; Disease-specific survival; Recurrence
references.citation: Cancer Res. 1989 May 1;49(9):2398-404
references.pmid: 2706627
references.citation: Future Oncol. 2011 Jun;7(6):753-65
references.pmid: 21675838
references.citation: Endocr Relat Cancer. 2011 Jul 04;18(4):C19-24
references.pmid: 21613412
references.citation: Breast Cancer Res. 2013 Jan 21;15(1):R5
references.pmid: 23336272
references.citation: Cell. 1997 Feb 7;88(3):405-15
references.pmid: 9039267
references.citation: Oncol Rep. 2002 Mar-Apr;9(2):409-16
references.pmid: 11836618
references.citation: Genes Dev. 1998 Nov 15;12(22):3488-98
references.pmid: 9832502
references.citation: Oncogene. 1996 Jun 6;12(11):2315-24
references.pmid: 8649771
references.citation: Breast Cancer Res. 2012 Apr 04;14(2):R57
references.pmid: 22475046
references.citation: Cancer Discov. 2012 Jun;2(6):503-11
references.pmid: 22628410
references.citation: Pathol Int. 2003 Feb;53(2):74-80
references.pmid: 12588434
references.citation: J Clin Oncol. 2005 Jun 20;23(18):4215-24
references.pmid: 15961768
references.citation: Clin Cancer Res. 1999 Aug;5(8):2069-76
references.pmid: 10473088
references.citation: J Clin Oncol. 1999 May;17(5):1474-81
references.pmid: 10334533
references.citation: Mod Pathol. 1995 Jun;8(5):560-7
references.pmid: 7675778
references.citation: Breast Cancer Res Treat. 2012 Nov;136(1):161-8
references.pmid: 22976805
references.citation: Br J Cancer. 2001 Apr 20;84(8):1064-9
references.pmid: 11308255
references.citation: Breast. 2006 Dec;15(6):718-27
references.pmid: 16675218
references.citation: Mol Pathol. 1999 Apr;52(2):78-83
references.pmid: 10474686
references.citation: Br J Cancer. 2004 May 17;90(10):1942-8
references.pmid: 15138475
references.citation: Mol Cell Biol. 1998 Aug;18(8):4499-508
references.pmid: 9671459
references.citation: Oncogene. 1995 Sep 7;11(5):885-91
references.pmid: 7675447
references.citation: Jpn J Clin Oncol. 2007 Sep;37(9):708-14
references.pmid: 17940078
references.citation: Breast Cancer Res Treat. 1999 Jul;56(2):105-12
references.pmid: 10573103
references.citation: Br J Cancer. 1996 Mar;73(6):728-34
references.pmid: 8611372
references.citation: Cell Cycle. 2010 May 15;9(10):1918-28
references.pmid: 20473028
references.citation: Mol Endocrinol. 1996 May;10(5):488-98
references.pmid: 8732680
references.citation: Cancer Res. 1995 Oct 1;55(19):4257-63
references.pmid: 7671232
references.citation: Cell. 2012 May 25;149(5):994-1007
references.pmid: 22608083